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ABSTRACT
Introduction: Falls and fall-related injuries are a
serious cause of morbidity and cost to society. Foot
problems and inappropriate footwear may increase the
risk of falls; therefore podiatric interventions may play
a role in reducing falls. Two Cochrane systematic
reviews identified only one study of a podiatry
intervention aimed to reduce falls, which was
undertaken in Australia. The REFORM trial aims to
evaluate the clinical and cost-effectiveness of a
multifaceted podiatry intervention in reducing falls in
people aged 65 years and over in a UK and Irish
setting.
Methods and analysis: This multicentre, cohort
randomised controlled trial will recruit 2600
participants from routine podiatry clinics in the UK
and Ireland to the REFORM cohort. In order to detect
a 10% point reduction in falls from 50% to 40%, with
80% power 890 participants will be randomised to
receive routine podiatry care and a falls prevention
leaflet or routine podiatry care, a falls prevention
leaflet and a multifaceted podiatry intervention. The
primary outcome is rate of falls (falls/person/time)
over 12 months assessed by patient self-report falls
diary. Secondary self-report outcome measures
include: the proportion of single and multiple fallers
and time to first fall over a 12-month period; Short
Falls Efficacy Scale—International; fear of falling in the
past 4 weeks; Frenchay Activities Index; fracture rate;
Geriatric Depression Scale; EuroQoL-five dimensional
scale 3-L; health service utilisation at 6 and
12 months. A qualitative study will examine the
acceptability of the package of care to participants and
podiatrists.
Ethics and dissemination: The trial has received a
favourable opinion from the East of England—
Cambridge East Research Ethics Committee and
Galway Research Ethics Committee. The trial results
will be published in peer-reviewed journals and at
conference presentations.
Trial registration number: Current Controlled Trials
ISRCTN68240461assigned 01/07/2011.
BACKGROUND
Falls and fall-related injuries are a serious
cause of morbidity and cost to society,1 a
burden which will increase with an ageing
population. The National Service Framework
(NSF) for Older People2 recognises the
importance of fall-related injuries, and calls
for health improvement plans to be devised
that will reduce this burden.
It is well recognised that falls result from
interactions between environmental hazards,
a variety of medical conditions and physio-
logical risk factors.3 Foot problems may also
increase the risk of falls. Foot problems affect
one in three community dwelling people
over the age of 65 years4 and are associated
with reduced walking speed and difﬁculty in
performing activities of daily living.5–7
There have been two relevant Cochrane
reviews on falls prevention, one relating to
falls in community dwelling older people8
and one focusing on falls in hospitals and
aged care facilities.9 At the time of designing
Strengths and limitations of this study
▪ This study is the first UK study evaluating the
clinical and cost-effectiveness of podiatric care
combined with footwear advice and provision (if
required), orthotic inserts and foot and ankle
exercises for falls prevention in people over
65 years of age.
▪ This study uses the novel cohort randomised
controlled trial design.
▪ The study uses an unblinded, patient self-report
primary outcome measure.
▪ It will not be possible to determine the clinical
and cost-effectiveness of this intervention in
patients who fall but do not receive routine
podiatry care.
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the study neither identiﬁed any randomised controlled
trials (RCTs) focusing on podiatry-related interventions.
A subsequent update has identiﬁed one trial of a
podiatry-based intervention for the prevention of falls10
which related to the Australian healthcare system
There is some evidence to suggest that foot problems
are associated with an increased risk of falling. Menz
et al’s6 prospective study of 176 older people identiﬁed
ankle ﬂexibility, toe plantarﬂexor strength and plantar
sensation as signiﬁcant and independent predictors of
balance and functional test performance. These factors
were later conﬁrmed as predictors of falling during a
12-month follow-up of that cohort, in which foot pain
was also identiﬁed as a predictor of falling.11 Mickle
et al’s12 13 prospective study of 312 people over 60 years
of age also found that fallers had signiﬁcantly higher
prevalence of foot pain, and displayed signiﬁcantly less
strength of the hallux and were more likely to have
hallux valgus and lesser toe deformities.
Inappropriate footwear may also impair balance and
increase the risk of falling. Footwear characteristics con-
sidered detrimental to balance include high heels, soft
soles and inadequate slip resistance.14 15 Prospective
studies have shown that walking barefoot or wearing
only stockings inside the home and wearing shoes with
an increased heel height and smaller contract area
increases the risk of falling.16–18 People who have a
history of falling are at increased risk of falls.19
Given the emerging evidence that foot problems and
inappropriate footwear increase the risk of falling, it has
been suggested that podiatry may have a role to play in
falls prevention, with several guidelines recommending
that older people have their feet and footwear examined
by a podiatrist.20 21
Several studies have also suggested that some treat-
ments provided by podiatrists, such as lesion debride-
ment,22 foot orthoses,23 foot and ankle exercises24 25
and footwear advice may play a role in improving
balance. Combining these therapies should allow for sta-
bility and improved function to be achieved at each
level. Lesion debridement can improve function during
gait if pain is reduced, exercise programmes focus on
internal strengthening and ﬂexibility and appropriate
footwear with orthotic devices can provide external
support, improved kinaesthesia and improved function.
A trial conducted in Australia in 305 community dwell-
ing older people with disabling foot pain showed a 36%
reduction in falls for those receiving a multifaceted
podiatry intervention, consisting of a foot orthosis,
advice on footwear, subsidy for new footwear, a home-
based programme of foot and ankle exercises, a falls pre-
vention education booklet and routine podiatry care for
12 months.10 26 The control group received only routine
podiatry care for 12 months which consisted of toenail
maintenance and scalpel debridement of hyperkeratotic
lesions (corns and calluses). There have been no further
large pragmatic trials looking at podiatric care combined
with footwear advice, foot and ankle exercise and
orthotic inserts for falls prevention, and there has been
no assessment of whether such an intervention is eco-
nomically viable within the UK healthcare setting. The
REFORM (REducing Falls with ORthoses and a
Multifaceted podiatry intervention) trial aims to address
these issues. The main objectives are to investigate the
clinical and cost-effectiveness of a multifaceted podiatry
intervention for falls prevention and to assess views and
experiences of the intervention and the trial process
from the perspective of the participants and podiatrists.
METHODS AND ANALYSIS
Design
The REFORM study is a ‘cohort randomised controlled
trial’ (cRCT). First we will recruit participants to the
REFORM cohort and while this is being assembled, we
will invite a selection of eligible participants from the
site undertaking the pilot phase to take part in a
REFORM pilot study. Once the pilot study is complete,
we will then invite the remaining eligible participants to
take part in the main REFORM trial. The REFORM
main trial is a two arm, pragmatic, open, multicentre,
randomised controlled trial with a 12-month follow-up.
REFORM study objectives for the pilot phase
1. To demonstrate the feasibility of recruiting to the
REFORM cohort.
2. To develop and pilot the multifaceted podiatry inter-
vention including a foot and ankle exercise pro-
gramme, supplementary DVD and booklet with
approximately 60 participants.
3. To develop the podiatrist training package.
4. To pilot the falls calendar and other patient data col-
lection questionnaires.
5. To assess participants’ views and experiences of the
intervention and the trial process.
6. Pilot, review and reﬁne if necessary recruitment
methodology for the main trial.
All these objectives were achieved and the pilot has
moved seamlessly into the main REFORM trial.
REFORM study objectives for the main study
This study will aim to address the following:
1. To train the podiatrists to deliver the intervention.
2. To examine the clinical and cost-effectiveness of the
multifaceted podiatry intervention for falls prevention.
3. To assess the podiatrists’ views and experiences of the
intervention and trial process.
Participants
Participant recruitment
Participants will be recruited from NHS podiatry clinics
based in either primary or secondary care in the UK
and one international site in the Republic of Ireland.
The rationale for recruiting only from podiatry clinics is
due to the logistical constraints imposed by the require-
ment for the control group to receive routine podiatry
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care. While it would be possible to recruit from GP prac-
tices, many of the patients identiﬁed in this setting
would not be receiving routine podiatry care, and NHS
podiatry service managers indicted that they would not
have the capacity to see large numbers of additional
patients.
Podiatrists within the NHS Trust or clinic at the
Republic of Ireland or the REFORM research podiatrist
will undertake a search of either electronic or paper
patient medical notes to identify potential participants
for the study. Patients aged 65 years and over who are
registered with the service and have attended routine
podiatry services within the past 6 months of the search
being undertaken will be identiﬁed and will be eligible
for an invitation mailing. Patients who have attended
high-risk clinics, (eg, diabetes clinics), or who live in a
nursing home will be excluded from the invitation mail
out. Sites will be requested where possible to screen out
patients in the following groups: patients with a life
expectancy of less than 6 months; patients known to
have dementia, a neurodegenerative disorder, neur-
opathy, a lower limb amputation or are chair or bed
bound. All eligible patients will be sent an invitation
pack (letter of invitation, participant information sheet,
consent form, screening questionnaire and prepaid
envelope) asking whether they would like to participate
in the REFORM study. Where the clinic has the capacity,
potential participants attending routine podiatry clinics
may be approached opportunistically. Where a multidis-
ciplinary team exists, other healthcare professionals such
as occupational therapists, falls practitioners and phy-
siotherapists may support the opportunistic recruitment.
Participants wishing to take part in the REFORM study
will be asked to return their completed consent form
and screening questionnaire by post to the York Trials
Unit (YTU). Researchers at the YTU will assess the
returned screening forms for participant eligibility.
During the consenting stage, potential participants will
be informed of the possibility of participating in other
related studies, for example, an associated qualitative
study and they will be asked to indicate (by ticking a box
on the consent form), if they would prefer not to be
approached about these studies. Participants can with-
draw from the study at any point. The reason for with-
drawal will not have to be declared; however, if provided,
this will be recorded. Data will be retained for all partici-
pants up to the date of withdrawal, unless a participant
speciﬁcally requests their details be removed. All data
returned to the York Trials Unit by participants will be
held in accordance with the Data Protection Act 1998.
Inclusion criteria for the REFORM cohort
All eligible, consenting participants will be asked to com-
plete a baseline questionnaire. Participants who return
valid baseline data will be included in the REFORM
cohort. Any participant reporting a score of 10 or more
on the Geriatric Depression Scale27 28 that is, more
severe depression, will be referred to their general prac-
titioner (GP).
Exclusion criteria for the REFORM cohort
Participants will be ineligible for the REFORM cohort if
they are under 65 years of age; report having neur-
opathy, dementia or other neurological condition
such as Parkinson’s disease, Alzheimer’s, multiple
sclerosis, Lou Gehrig’s/amyotrophic lateral sclerosis or
Huntington’s disease; are unable to walk household dis-
tances (10 m) without the help of a walk aid such as a
Zimmer frame or walker or person to assist; have had a
lower limb amputation; or are unwilling to attend their
podiatry clinic.
Inclusion criteria for the REFORM trial
Participants will be eligible for the REFORM trial if they:
1. Have had one fall in the past 12 months; or one fall
in the past 24 months requiring hospital attention; or
report a fear of falling on their baseline question-
naire that is, have worried about falling at least some
of the time, in the past 4 weeks;
2. Are community dwelling.
Exclusion criteria for the REFORM trial
Participants who do not complete the baseline or run-in
data collection instruments adequately, or who are
unable to read or speak English will be excluded from
the trial.
Participants who do not wish to take part in the study
Participants who do not wish to take part in the main study
are not required to return any forms to the YTU. However,
all participants in the pilot phase of the study who are sent
an invitation pack will be given the opportunity to decline
participation and if willing, provide some demographic
information and reason for declining. This will provide us
with sufﬁcient information to document the reasons why
participants do not wish to take part in the study and will
allow us to compare decliners to those who are participat-
ing. The recruitment pack in the main mail out will not
contain a decline form.
Sample size
The REFORM cohort
We propose to recruit up to 2600 participants into the
REFORM cohort to allow us to sample for the pilot trial
and to allow cohort attrition before we sample for the
main REFORM trial.
Internal pilot phase
Pilot trial: In order to pilot the intervention, a random
sample of 60 participants will be selected from the
REFORM cohort. Participants will be allocated equally
to each of the two groups that is, 30 participants per
group. The allocation sequence will be computer gener-
ated by the YTU randomisation service and will be strati-
ﬁed by centre.
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REFORM main trial
The REFORM trial is designed to detect a 10% point
reduction in the number of people who fall over a
12-month period. Assuming this high-risk group has an
underlying risk of falling in a 12-month period of 50%29
then in order to observe a reduction to 40% with 80%
power and a two-sided 5% signiﬁcance level we would
require 890 participants (445 in each group, allowing
for a 10% loss to follow-up).
Randomisation
Participants who fulﬁl the eligibility criteria for the
REFORM trial and who have provided written consent
to take part in the study will be eligible for randomisa-
tion. Randomisation will be carried out by the YTU
secure remote computer randomisation service. Eight
hundred and ninety participants will be randomly allo-
cated in a 1:1 ratio to either the intervention or control
group. If more than 890 eligible participants are
recruited then we will randomly allocate the remaining
participants in a 2:1 ratio in favour of the control group.
This will allow us to increase the power of the study,
without putting patients at any additional risk and
without incurring additional costs. In order to allow for
manageable case-loads at individual sites, the randomisa-
tion is by permuted blocks and stratiﬁed by centre. The
YTU will write to the participant’s GP informing them of
study participation and to participants who are allocated
to the intervention group.
Blinding
Owing to the nature of the intervention, blinding of par-
ticipants will not be feasible. Blinding of members of the
study team who are actively involved in the administra-
tion of the study and may collect primary outcome falls
data or undertake data queries on secondary outcomes,
or the health economist will not be possible. Members
of the study team responsible for data entry and the stat-
istical analysis of the study will be kept blind to group
allocation.
Intervention group
Participants allocated to receive the intervention will be
seen by the podiatrist at the clinic they would normally
attend for routine podiatry care, as soon as possible after
randomisation. Participants are invited to attend two
podiatry visits approximately 2–4 weeks apart, with
further appointments if required in addition to their
usual podiatry care.
Footwear advice and provision
Participants’ everyday footwear (indoor and outdoor
footwear) will be assessed according to the following
characteristics: appropriate size; method of fastening;
height and width of the shoe’s heel; thickness of outsole;
heel counter stiffness; longitudinal sole rigidity; sole
ﬂexion point and tread pattern. Footwear will be deemed
to be inappropriate if the shoes have any of the following
characteristics: (1) heel height is greater than 4.5 cm; (2)
no adjustable ﬁxation of the upper; (3) no heel counter
or the heel counter can be depressed to greater than 45°;
(4) a fully worn/smooth/thin sole; (5) the shoe heel
width is narrower than the participant’s heel width by
greater than or equal to 20%; or (6) incorrect shoe
size.10 Participants with inappropriate footwear will be
counselled regarding the hazardous footwear feature(s)
identiﬁed during the assessment and will be advised on
safer characteristics for future footwear purchases. Where
possible, footwear will be provided for participants whose
footwear is deemed to be inappropriate. The podiatrist
will order shoes directly from two companies participat-
ing in the Healthy Footwear Guide (HFG) scheme30; DB
shoes (Rushden, UK) or Hotter company (Skelmersdale,
UK). As not all of the shoes manufactured by these com-
panies fulﬁl the characteristics of a safe shoe, the trial
team will assess the shoes and provide a list of suitable
footwear from which participants can choose. In order to
avoid incentivising patients to take part in the study, parti-
cipants will only be told about footwear provision, if they
are deemed to need new footwear. During the REFORM
pilot trial we will explore the feasibility of making a foot-
wear assessment, providing footwear advice and provision
of footwear and if necessary we will revise the interven-
tion if needed.
Foot orthoses
We originally planned to use the same orthotic device
(Formthotics, Foot Science International, Christchurch,
New Zealand) (ﬁgure 1) as our Australian collabor-
ator10 26 as they had demonstrated that this device, com-
monly used in Australia, was acceptable to patients and
was shown to be associated with a reduction in falls.
However, during the setup period of the pilot phase of
the REFORM trial, podiatrists at the recruiting sites
reported difﬁculties when ﬁtting these devices with the
addition of posting (the application of wedges under the
forefoot or rearfoot) and the ease of ﬁtting in patient’s
current shoes. These sites frequently use the x-line
Figure 1 Formthotic orthotic device (colour for on-line
version/monochrome for other format).
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orthoses range (Healthystep, Mossley, UK; ﬁgure 2) as
they are easy to modify and are easy to ﬁt in patient’s
current shoes. During the pilot trial we will provide parti-
cipants with both types of device to determine which
device is most acceptable to a UK population. The
Formthotics device will be issued as per the manufactur-
ing guideline using the appropriate heating equipment
and ﬁtting procedure. The x-line PressurePerfect/
Standard device will be ﬁtted and if indicated, modiﬁed
to improve foot posture as assessed in usual clinical prac-
tice by the individual clinician. If a participant already
has insoles, whether shop bought or prescribed, the clin-
ician will make a clinical judgement on the suitability of
replacing their current insole with the trial insole. If the
current insole is replaced with the trial insole then any
current prescription/modiﬁcations maybe repeated, if
applicable. We would consider the insole component of
the intervention already addressed if the clinician felt it
detrimental to replace their current insole with that of
the trial insole. If the podiatrist feels that the patient
requires more than what the current or trial insole can
provide, or if they present with a musculoskeletal path-
ology, then a referral will be made in line with routine
practice.
Home-based foot and ankle exercise programme
Participants will be prescribed a 30 min home-based
foot and ankle exercise programme which will be
undertaken three times per week, indeﬁnitely. The
exercise programme is aimed at stretching and
strengthening the muscles of the foot and ankle. The
exercises will be based on the programme developed by
Spink et al10 26 and will be adapted to make it suitable
for a UK setting during the pilot phase of the trial.
A summary of the individual exercises is given in
table 1. The exercises will be demonstrated by the
podiatrist and will be supplemented by a DVD and an
illustrated explanatory booklet. Participants will be
assessed for competence and safety at the baseline and
follow-up appointments.
Routine podiatry care
Routine podiatry care will continue to be given at separ-
ate podiatry appointments in accordance with partici-
pant’s usual care. This will aim to reduce painful
conditions such as corns and callouses, that have been
found to be associated with an increased risk of falls.
Falls prevention leaflet and trial newsletter
Participants will receive a copy of the latest falls preven-
tion advice leaﬂet produced by Age UK (the current
version ‘Staying steady’ was printed in June 2010). This
leaﬂet will be sent to the participant in the post with
their baseline questionnaire.
Participants will be sent a site and group speciﬁc newslet-
ter at 3 and 12 months informing them about progress of
the study. The intervention group’s newsletter will include
a section about the foot and ankle exercises in order to
aid compliance. All participants will receive £5 in recogni-
tion of their participation and to offset any incidental
expenses associated with completing the questionnaires.
Control group
Participants allocated to the control group will receive
the same falls prevention advice leaﬂet produced by Age
UK. This leaﬂet will be sent to the participant in the
post with their baseline questionnaire. Participants will
continue to receive routine podiatry and GP access in
accordance with their usual care. Participants will also
be sent a site and group-speciﬁc newsletter at 3 and
12 months. All participants will receive £5 in recognition
of their participation and to offset any incidental
expenses associated with completing the questionnaires.
Primary outcome measure for the REFORM trial
The primary outcome is the rate of falls (ie, falls/person/
time) where a fall is deﬁned as ‘an unexpected event in
which the participant comes to rest on the ground, ﬂoor,
or lower level’.31 Data will be collected via participant self-
reported monthly falls calendars throughout the
12 months following randomisation. Participants will be
asked to record each day whether or not they had any fall.
Participants who do not return their falls calendar within
1 week of the due date will be telephoned by the YTU to
obtain the missing data. Participants will also be given a
Freephone number to report any falls as soon as possible
after the fall. Information collected includes: date and
location of fall; reason for fall; any injuries sustained (eg, a
superﬁcial wound or a broken bone); hospital admissions;
footwear worn at the time of the fall; and if the patient was
wearing an orthotic or using a walking aid. As we are col-
lecting falls data at 6 and 12 months follow-up, these data
will be used for those participants who do not return their
monthly falls calendar.
REFORM trial secondary outcome measures
All secondary outcomes are self-reported by the patient
and collected by questionnaire at baseline, 6 and
12 months, or by monthly falls calendars. Secondary
Figure 2 X-line orthotic device (colour for on-line version/
monochrome for other format).
Cockayne S, et al. BMJ Open 2014;4:e006977. doi:10.1136/bmjopen-2014-006977 5
Open Access
Table 1 Summary of the home-based foot and ankle exercises
Activity Description Dosage Increments
Ankle range of motion/
warm up
Sitting with the knee at 90°. Lift the foot to clear the ground and
then rotate the foot slowly in a clockwise direction and then an
anticlockwise
1×10 repetitions for each foot in
each direction
None
Ankle inversion strength Sitting upright, hip, knee and ankle at 90°. Invert foot against
resistive exercise band. The band should be fixed at 90° to the
foot from an additional chair/table leg
3×10 repetitions for each foot Increase resistance strength of
resistive exercise band
Ankle eversion strength Sitting upright, hip, knee and ankle at 90°. Evert foot against
resistive exercise band The band should be fixed at 90° to the
foot from an additional chair/table leg
3×10 repetitions for each foot Increase resistance strength of
resistive exercise band
Ankle dorsiflexion strength Sitting, hip, knee and ankle at 90°.
Dorsiflex both feet to end range of motion and hold.
Keep pulling feet up towards the body during the hold
Hold feet in dorsiflexion for 3×10 s Increase repetitions up to
maximum of 10
Intrinsic strengthening, toe
plantarflexion strength and
toe stretch
Sitting, hip, knee and ankle at 90°.
1. Use the therapy ball under the toes to stretch the toes. The
rest of the foot should be plantargrade. Then curl and point
the toes up and over the ball.
2. Use the therapy ball under the toes to stretch the toes. The
rest of the foot should be plantargrade. With the heel on/
close to the floor, curl the toes over the ball and attempt to
pick up the ball with the toes
3×10 repetitions for each exercise
both feet. Have a 30 sec break
between each repetition
Increase up to a maximum of
50 repetitions
Ankle plantarflexion strength From standing position, rise up onto toes of both feet and then
slowly lower back down. Just before the heels contact the floor,
rise back up onto the toes
3×10 repetitions Increase repetitions up to
maximum of 50
Calf stretch Facing a wall and using hands on the wall for balance, step one
foot in front of the other keeping feet hip width apart and hips,
knees and feet facing the wall. Bend the knee closest to the wall
and keep the back leg straight. Keep both heels in contact with
the floor
Hold stretch for 3×20 s on each leg Increase the stride length and
forward lean to increase the
stretch
Proprioception/balance
training
From a standing position and holding on to a work surface/chair/
wall for support, stand on one leg. Repeat on the other side
Hold for 30 s.
Repeat 3 repetitions
Increase slowly to hold for
1 min per repetition.
If competent, rise up on to toes
on the one supporting leg: 3×10
repetitions
6
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outcomes include: proportion of fallers (single and mul-
tiple); patient reported time to ﬁrst fall during follow-up;
health-related quality of life as measured by the
EuroQoL-ﬁve dimensional scale (EQ-5D)32; fear of falling
as measured by the question, ‘During the past 4 weeks
have you worried about having a fall?’, fear of falling as
measured by the Short Falls Efﬁcacy Scale—International
(FES-I),33 activities of daily living as measured by the
Frenchay Activities Index (FAI),34 fracture rate, health
service utilisation and depression as measured by the short
form Geriatric Depression Scale (GDS).28
Nested qualitative study
A qualitative evaluation will be carried out to examine
the acceptability of the intervention as a whole package
of care, to both the trial participants and the podiatry
practitioners. Trial participants from the pilot phase of
the study who are receiving the intervention will be
asked about their experience of the intervention.
Particular attention will be paid to the acceptability and
compliance with the foot orthosis, exercise programme,
podiatry service and footwear advice/purchase and how
the intervention ﬁts into the individual’s wider experi-
ence of balance problems within their everyday lives.
Ten to 15 participants will be purposively selected from
the pilot phase of the trial (the ﬁrst 60 participants rando-
mised) to ensure a representative spread according to falls
history, age and gender. This maximum variation sampling
approach35 will ensure a wide range of viewpoints are
included in the data collection and analysis. Participants will
be invited to attend a face-to-face interview or, if prefered, a
telephone interview. Written informed consent will be
obtained from the participant prior to the interview. The
semistructured interviews will be conducted within approxi-
mately 2 weeks of receiving the 6-month follow-up
questionnnaire. A follow-up telephone interview will be con-
ducted within 2 weeks of receiving the 12-month follow-up
questionnaire to discuss any changes (or not) recorded in
the outcomes measured over the longer term follow-up
period. All interviews will be conducted using a topic guide
to ensure consistency across participants. However, the
format will be ﬂexible in order to allow participant-led data
regarding what they constitute as important and/or success-
ful in terms of treatment outcome.
We will interview a purposive sample of 5–10 practi-
tioners who are providing the podiatry services for the
study regarding the way in which they have delivered the
intervention, the ease of delivery, their conﬁdence in
the intervention, and their experience of being involved
in the trial. Face-to-face or telephone interviews will be
conducted approximately 3 months into the trial
process. Informed consent will be obtained prior to the
interview being conducted.
Adverse events
Details of any adverse events reported to the YTU either
directly by the participant or by a member of the
research team at the recruiting site will be recorded.
This study will report details of any serious adverse
events (SAEs) that are required to be reported to the
Research Ethics Committee (REC) under the current
terms of the Standard Operating Procedures for RECs.
A SAE is deﬁned as any untoward occurrence that:
1. Results in death;
2. Is life threatening;
3. Requires hospitalisation or prolongation of existing
hospitalisation;
4. Results in persistent or signiﬁcant disability or
incapacity;
5. Consists of a congenital anomaly or birth defect, or
6. Is otherwise considered medically signiﬁcant by the
investigator.
An event is deﬁned as ‘related’ if the event was due to
the administration of any research procedure. An ‘unex-
pected event’ is deﬁned as a type of event not listed in
the protocol as an expected occurrence. Expected
events include: aches and pains in the lower limb lasting
for longer than 48 h; fall; new callus/corn formation,
blisters, ulcers; skin irritation/injury including pressure
sores and soft tissue injury.
In the context of this study, an occurrence of the type
listed in (1) to (6) will be reported as an SAE only if:
1. The event is suspected to be related to an aspect of
the research procedures (eg, wearing the orthotic,
undertaking the exercise programme, completion of
follow-up questionnaires, participation in feasibility
or qualitative substudies, telephone contact), and;
2. It is an unexpected occurrence. Hospitalisations, dis-
abling/incapacitating/life-threatening conditions, falls
and deaths are expected in the study population due
to the age of the cohort, they will therefore only be
reported as SAEs if they appear to be related to an
aspect of taking part in the study.
Other data collected
Treatment details will be recorded by the podiatrist
including: the number of podiatry visits; an eligibility
checklist with details on relevant health conditions and
test results; characteristics of current indoor and
outdoor shoes; details relating to shoes ordered; details
on the type and prescription of any current insole use;
the type of insole issued/retained with any modiﬁcations
made, and any amendments or advice given on the
intervention due to safety reasons.
Information on adherence to the exercise, footwear
advice and orthotic components of the intervention will
be collected from participant self-reported questionnaire
data at three, 6 and 12 months. Participants will be asked
whether during the past month, they were wearing their
orthotic ‘all of the time’, ‘most of the time’, ‘some of the
time’, ‘a little of the time’ or ‘none of the time’.
Participants will also be asked, for the past month, typically
how many times a week they did the exercises: none, one,
two, three or more than three times. Participants will be
asked at 12 months if they were given footwear advice, and
whether or not they followed any given advice.
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Statistical analysis
There will be a single analysis at the end of the trial,
conducted using STATA (StataCorp, 4905 Lakeway Drive,
College Station, Texas 77845, USA). All analyses will be
conducted on an intention-to-treat basis, that is, includ-
ing all randomised patients in the groups to which they
were assigned. All tests will be two-sided at the 5% sig-
niﬁcance level. If more than 890 participants are
recruited and unequal allocation is utilised, then ana-
lyses will be adjusted to take this into account.
i. The REFORM cohort
Descriptive statistics will be presented for participants
in the REFORM cohort.
ii. REFORM trial
Participant baseline data will be summarised descrip-
tively by randomised arm. No formal statistical compari-
sons will be undertaken. Continuous measures will be
reported as means and SDs while the categorical data
will be reported as counts and percentages.
iii. Statistical analysis of the REFORM trial primary
outcome
The number of falls per person will be analysed using
a Poisson regression model adjusting for gender, age,
centre and history of falling to estimate the difference in
falls rate between the groups. If there is over dispersion,
a negative binomial regression model adjusting for the
same factors will be used.36 Point estimates and their
associated 95% CIs will be provided.
iv. Statistical analysis of the REFORM trial secondary
outcomes
The proportion of fallers versus non-fallers in each
group will be compared by logistic regression adjusting
for gender, age, centre and history of falling. ORs and
their associated 95% CIs will be provided. The propor-
tion of multiple fallers versus single or non-fallers in
each group will be compared over the 12-month trial
period using logistic regression adjusting for gender,
age, centre and history of falling.
The time to the ﬁrst fall will be derived as the number of
days from randomisation until the patient reports having a
fall as detailed from the participant’s falls calendar, falls
telephone data collection sheet or self-reported question-
naire. Participants who have not had a fall will be treated
as censored at their date of trial exit, or date of last avail-
able assessment or 365 days/trial cessation, as appropriate.
The proportion of patients yet to experience a fall will be
summarised by a Kaplan-Meier survival curve for each
group. The time to ﬁrst fall will be analysed by Cox propor-
tional hazard regression adjusting for gender, age, centre
and history of falling. HRs and their associated 95% CIs
will be provided. The proportional hazard assumption will
be evaluated using Schoenfeld residuals. The median time
to the ﬁrst fall and its associated 95% CIs will be estimated
from this adjusted model.
Patients with a score of six or more on the short form
Geriatric Depression Scale will be categorised as having
depression. The proportion of people with depression in
each group will be compared over the 12-month trial
period using logistic regression adjusting for gender,
age, centre and history of falling.
The following secondary outcomes: Short Falls
Efﬁcacy Scale—International, fear of falling in the past
4 weeks, and the Frenchay Activities Index will be
treated as continuous data and will be measured at base-
line, month 6 and 12. A covariance pattern model
incorporating all post randomisation time points will be
used to compare the two groups on these outcomes
adjusting for baseline score, gender, age, centre and
history of falling. The correlation of observations within
patients over time will be modelled and the model
effects and their associated 95% CIs will be provided.
The proportion of patients obtaining at least one frac-
ture over the 12-month follow-up period will be compared
by logistic regression adjusting for gender, age, centre and
history of falling. ORs and their associated 95% CIs will be
provided. If there are patients that obtain multiple frac-
tures in this time (from different events), then the propor-
tion of patients obtaining multiple fractures versus single
or no fractures in each group will be compared over the
12-month trial period using logistic regression adjusting
for gender, age, centre and history of falling.
v. Intervention adherence
Descriptive statistics will be used to summarise the
adherence to the exercise and orthotic at 3, 6 and
12 months and adherence to following footwear advice.
A Complier Average Causal Effect (CACE) analysis to
assess the impact of compliance on treatment estimates
will be considered.
vi. Missing data
The amount of missing data will be reported for each
randomised arm.
vii. Qualitative analysis
All interviews will be audio recorded digitally and tran-
scribed verbatim. The computer package ATLAS-ti will
be used to manage the data. Data will be analysed
according to the constant comparison method through
thematic coding of the data.37 Coding will take place
using a combination of a priori themes (according to
the aims of the qualitative study and the outcome mea-
sures of interest to the trial) and emergent themes.
However, in addition, as participants in the qualitative
sample would also have responses to the quantitative
data collected for the trial, this will allow for the possibil-
ity of taking a mixed-methods approach to data integra-
tion, in which the two forms of data can be used in a
complementary way.38
viii. Adverse event data
Adverse event data will be summarised descriptively by
randomised arm.
Economic evaluation
The economic analysis will be performed using individ-
ual patient level data from the REFORM trial. The ana-
lytical approach will take the form of cost-effectiveness
and cost-utility analyses. The cost-effectiveness approach
will assess value for money in terms of cost per fall
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averted, and the cost-utility analysis will assess cost per
quality adjusted life year (QALY) gained. The perspec-
tive for both analyses will be that of the UK NHS and
Personal Social Services39 as well as that of society.
Discounting for future cost and health beneﬁt will not
be included considering the time frame for the trial is
12 months after randomisation. The year of pricing will
be set as the mid-year of the trial.
Health beneﬁts associated with the treatments will be
measured in terms of both estimates of the mean
number of falls, corresponding to the main outcome of
the trial, and mean QALYs, which is deﬁned as a year
lived with full health. The EQ-5D40 will be used to elicit
patient utility values at different points in time and used
to calculate QALYs for each patient using the area
under the curve.41 These utility values are used as
‘quality adjustment’ for each patient’s survival time.
Mean within-trial estimates of cost and health beneﬁts
will be estimated using the regression approach to allow
for the correlation between costs and effects as well as
adjusting for covariates. This analysis will also account for
skewness and censoring associated with time to event and
cost data.42–44 The result will be presented as incremental
cost-effectiveness ratio (ICER) where the difference of
mean cost estimates between two arms are divided by the
difference of mean health beneﬁt between two arms. The
Net Monetary Beneﬁt (NMB) will be also presented.45
The NMB provides an estimation of the gain (or loss) in
resources of investing in a particular intervention when
those resources might be used elsewhere.46
The uncertainty surrounding the decision to accept a
treatment as the most cost-effective will be explored in
cost-effectiveness acceptability curves (CEAC).47 These
curves depict the probability of accepting a treatment as
being cost-effective for a large range of willingness to
pay values for an extra unit of health beneﬁt. Sensitivity
analysis will be conducted to explore the impact of
underlying assumptions of the model and the range of
unit costs on the cost-effectiveness results.
Despite the careful design of any trial the presence of
missing data is unavoidable. The reasons for the presence
of incomplete data are multiple. Similarly there are dif-
ferent methods to handle its analysis.48 The pattern of
missing data for the economic analysis will be examined
and described. The multiple imputation (MI) process
has been recommended as the appropriate method to
address the uncertainty in the results of economic evalu-
ation due to missing data. Therefore, the base case ana-
lysis will be based on the MI, while the complete case
data set will be used for the sensitivity analysis.
The main outcome of the REFORM trial, fall reduc-
tion, could be regarded as an intermediate outcome to
achieve the ﬁnal target—the reduction in fracture.
However, due to the restriction in the length of
follow-up, the long-term effect of decreasing the
number of fractures, might not be observed within the
timeframe of the current trial. Therefore, a further ana-
lysis is planned to model the possible long-term impact
of the trial assuming that a falls reduction should also
lead to a fracture reduction.
A decision analytic model approach will be adopted to
perform such a task. The perspective will be the UK NHS
and Personal Social Services and the time horizon for
this analysis will be a life-time horizon. Life-time horizon
refers to following up every single participant in a
hypothetical cohort until the last participant dies. The
hypothetical cohort will be constructed, based on
the characteristics of the trial population, to estimate the
QALY yield and cost saving of the long-term effect of the
intervention. The model parameters which are not col-
lected in the trial will be extracted from the existing lit-
erature. The model outputs will be the estimated
expected mean costs, effectiveness, and QALYs associated
with each alternative treatment. Estimated total costs and
outcomes will be discounted properly according to the
current guidance of health technology appraisal.39
Uncertainty regarding cost-effectiveness will be evalu-
ated using probabilistic sensitivity analysis, where inputs
into the analysis are deﬁned as probability distributions
which reﬂect uncertainty. The uncertainty surrounding
the decision to adopt a given treatment option as a cost-
effective treatment at different levels of willingness to
pay will be represented in acceptability curves. The
impact of assumptions undertaken in the analysis
regarding the evidence over parameters or relating to
the decision model (such as extrapolation) will be evalu-
ated in a sensitivity analysis, if possible.
ETHICS AND DISSEMINATION
Ethics
All participants will give written informed consent prior
to entry to the study.
Dissemination
Results of the study will be disseminated through, national
and international research conferences and in articles
published in international peer-reviewed journals.
DISCUSSION
This study uses the cohort randomised controlled trial
(cRCT) design. Existing trial designs have reported issues
around recruitment, ethics, patient preferences and treat-
ment comparisons.49 We chose this approach to ﬁnd out
whether the cRCT design can overcome these issues and
to test its feasibility. We anticipate that using this design
will offer the following advantages. First, we expect that
recruitment rates will be enhanced. Some participants
enrolled in the cohort will be immediately eligible for the
main trial and can be randomised straight away. Others,
however, will become eligible over time due to the fact that
they have subsequently had a fall. If an alternative design
had been chosen then these patients could not have been
included in the study and would have been lost. Second,
in this study participants are receiving routine podiatry
care outside of the trial and apart from altruistic reasons
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the only incentive to take part in the study is the possibility
of receiving the extra package of podiatry care. If a prag-
matic design had been used, then the control patients
would have been notiﬁed of their group allocation, and
this may have resulted in a higher attrition rate. If this had
occurred then there is the possibility that selection bias
could be introduced. In addition to this, participants may
also either knowingly or unknowingly bias the trial by
reporting the number of falls they have had less conscien-
tiously than those allocated to the intervention arm. In the
cRCT design, participants are only notiﬁed of their alloca-
tion to the intervention group. Control participants are
only aware of their participation in the study as a whole,
thereby minimising the possibility of introducing attrition
and reporting bias. Third, we expect that using the cRCT
design will help minimise postrandomisation attrition
rates. Unfortunately, many trials lose participants, and
unless this occurs in a random manner, there is the possi-
bility of selection bias being introduced. Many participants
are lost in the early stages of a study for example, partici-
pants change their mind. Using the cRCT design, which
effectively has a run-in period, allows the majority of
patients to withdraw from the study prior to randomisa-
tion, thereby minimising postrandomisation attrition rates.
Finally, one key feature of the cRCT design is the capacity
to undertake multiple randomised controlled trials over
time. Once this cohort is set up, we will apply for funding
to undertake further trials using the participants in this
study. This is not only a quick and cost-effective strategy to
identifying trial participants but has the added advantage
of reducing heterogeneity of trial populations enabling
synthesis of trial data and indirect comparisons between
trial treatments.
Falls in older people are a major health problem.
Podiatry may have a role in preventing falls as there is some
evidence to suggest that foot problems and inappropriate
footwear may increase the risk of falling. A recent trial by
Spink et al10 26 has demonstrated that a podiatric interven-
tion consisting of: footwear assessment and provision; foot
orthotic device and a home-based foot and ankle exercise
programme can reduce falls in patients aged over 65 years
of age with disabling foot pain. As far as we are aware, such
a multifaceted podiatry intervention has not been evaluated
in a UK and Republic of Ireland setting. The REFORM trial
aims to evaluate the clinical and cost-effectiveness of such a
package of care in patients over the age of 65 years who
have an increased risk of falling.
TRIAL STATUS
Recruitment and follow-up are in progress. Recruitment
to the study began in October 2012 and will continue
until approximately spring 2015. Patients will continue
to be followed-up until approximately spring 2016.
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